These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 26177431)
1. [CD200 protein, bad prognostic in patients with multiple myeloma]. Vela-Ojeda J; García-Ruiz Esparza MA; Padilla-González Y; Pérez-Retiguin F; Reyes-Maldonado E; Maillet D; Montiel-Cervantes LA Rev Med Inst Mex Seguro Soc; 2015; 53(4):438-43. PubMed ID: 26177431 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic significance of CD200 expression and its stability in plasma cell myeloma. Douds JJ; Long DJ; Kim AS; Li S J Clin Pathol; 2014 Sep; 67(9):792-6. PubMed ID: 24958785 [TBL] [Abstract][Full Text] [Related]
3. CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma. Olteanu H; Harrington AM; Kroft SH Am J Clin Pathol; 2012 Dec; 138(6):867-76. PubMed ID: 23161721 [TBL] [Abstract][Full Text] [Related]
4. Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma. Aref S; Azmy E; El-Gilany AH Hematol Oncol; 2017 Mar; 35(1):51-57. PubMed ID: 26033514 [TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents. Muccio VE; Saraci E; Gilestro M; Gattei V; Zucchetto A; Astolfi M; Ruggeri M; Marzanati E; Passera R; Palumbo A; Boccadoro M; Omedè P Cytometry B Clin Cytom; 2016 Jan; 90(1):81-90. PubMed ID: 26287276 [TBL] [Abstract][Full Text] [Related]
6. CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide. Tazawa S; Shiozawa E; Homma M; Arai N; Kabasawa N; Kawaguchi Y; Fujiwara S; Okino K; Kobayashi K; Yamochi T; Tate G; Nakamaki T; Takimoto M J Clin Exp Hematop; 2015; 55(3):121-6. PubMed ID: 26763359 [TBL] [Abstract][Full Text] [Related]
7. [Correlation between Expression of CD200 and Regulatory T Cells in Multiple Myeloma and Its Significance in Prognostic Stratification]. Zhu MX; Wan WL; Li HS; Wang YF; Wang J; Ling HS; Yan XX; Ke XY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1427-1432. PubMed ID: 27784369 [TBL] [Abstract][Full Text] [Related]
8. CD200 is a new prognostic factor in multiple myeloma. Moreaux J; Hose D; Reme T; Jourdan E; Hundemer M; Legouffe E; Moine P; Bourin P; Moos M; Corre J; Möhler T; De Vos J; Rossi JF; Goldschmidt H; Klein B Blood; 2006 Dec; 108(13):4194-7. PubMed ID: 16946299 [TBL] [Abstract][Full Text] [Related]
9. [Expression and clinical significance of Notch1 on the membrane of bone marrow CD38(+)CD138(+) plasma cells in the patients with multiple myeloma]. Zhao YR; Fu R; Guan J; Gao S; Liu H; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Wu YH; Song J; Wang HQ; Xing LM; Wang J; Li LJ; Shao ZH Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):274-7. PubMed ID: 22781716 [TBL] [Abstract][Full Text] [Related]
10. Role of interleukin 16 in multiple myeloma. Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance. Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871 [TBL] [Abstract][Full Text] [Related]
13. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416 [TBL] [Abstract][Full Text] [Related]
14. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma. Ak I; Gulbas Z Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019 [TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849 [TBL] [Abstract][Full Text] [Related]
16. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534 [TBL] [Abstract][Full Text] [Related]
17. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients. Kara IO; Sahin B; Paydas S; Cetiner S Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Alapat D; Coviello-Malle J; Owens R; Qu P; Barlogie B; Shaughnessy JD; Lorsbach RB Am J Clin Pathol; 2012 Jan; 137(1):93-100. PubMed ID: 22180482 [TBL] [Abstract][Full Text] [Related]
19. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Ghermezi M; Li M; Vardanyan S; Harutyunyan NM; Gottlieb J; Berenson A; Spektor TM; Andreu-Vieyra C; Petraki S; Sanchez E; Udd K; Wang CS; Swift RA; Chen H; Berenson JR Haematologica; 2017 Apr; 102(4):785-795. PubMed ID: 28034989 [TBL] [Abstract][Full Text] [Related]
20. Serum calcium is an independent prognostic factor of overall survival in Mexican patients with multiple myeloma. Maillet D; Montiel-Cervantes L; Padilla-González Y; Sánchez-Cortés E; Xolotl-Castillo M; Vela-Ojed J; Reyes-Maldonado E Rev Invest Clin; 2012; 64(1):17-24. PubMed ID: 22690525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]